Healthcare -
Biotechnology - NASDAQ - US
$ 0.74
1.37 %
$ 52.5 M
Market Cap
-1.61
P/E
1. INTRINSIC VALUE
Balance Sheet
Ovid Therapeutics Inc.
| Current Assets | 110 M |
| Cash & Short-Term Investments | 106 M |
| Receivables | 0 |
| Other Current Assets | 3.76 M |
| Non-Current Assets | 34.4 M |
| Long-Term Investments | 17.6 M |
| PP&E | 14.7 M |
| Other Non-Current Assets | 2.14 M |
| Current Liabilities | 11.5 M |
| Accounts Payable | 3.7 M |
| Short-Term Debt | 1.25 M |
| Other Current Liabilities | 6.53 M |
| Non-Current Liabilities | 44.8 M |
| Long-Term Debt | 14.8 M |
| Other Non-Current Liabilities | 30 M |
EFFICIENCY
Earnings Waterfall
Ovid Therapeutics Inc.
| Revenue | 392 K |
| Cost Of Revenue | 0 |
| Gross Profit | 392 K |
| Operating Expenses | 59.7 M |
| Operating Income | -59.3 M |
| Other Expenses | -6.94 M |
| Net Income | -52.3 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Ovid Therapeutics Inc.
| Net Income | -52.3 M |
| Depreciation & Amortization | 1.6 M |
| Capital Expenditures | -137 K |
| Stock-Based Compensation | 7.29 M |
| Change in Working Capital | 2.39 M |
| Others | -4.07 M |
| Free Cash Flow | -45.9 M |
Wall Street Analysts Price Targets
Ovid Therapeutics Inc.
Wall Street analysts predict an average 1-year price target for OVID of $7.33 , with forecasts ranging from
a
low of
$3 to a high of $11 .
OVID Lowest Price Target
Wall Street Target
3 USD
305.41%
OVID Average Price Target
Wall Street Target
7.33 USD
890.99%
OVID Highest Price Target
Wall Street Target
11 USD
1386.49%
4. DIVIDEND
ANALYSIS
OVID does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Ovid Therapeutics Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
50.4 K USD 1
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
10 months ago
Mar 18, 2024
|
Bought
50.4 K USD
|
LEVIN JEREMY M
CEO
|
+ 18248
|
2.76 USD |
|
2 years ago
Sep 12, 2022
|
Sell 37.3 K
USD
|
Tardio Jason
Chief Operating Officer
|
- 17344
|
2.15 USD |
|
3 years ago
Jul 14, 2021
|
Sell 126 K
USD
|
Rakhit Amit
President and CMO
|
- 34017
|
3.71 USD |
|
4 years ago
Aug 28, 2020
|
Bought
49.6 K USD
|
LEVIN JEREMY M
CEO
|
+ 8488
|
5.84 USD |
|
5 years ago
Oct 08, 2019
|
Bought
5 M USD
|
TAKEDA PHARMACEUTICAL CO LTD
10 percent owner
|
+ 2000000
|
2.5 USD |
|
5 years ago
Oct 08, 2019
|
Bought
150 K USD
|
LEVIN JEREMY M
CEO
|
+ 60000
|
2.5 USD |
|
5 years ago
Feb 26, 2019
|
Bought
20.2 K USD
|
Bernstein Karen
Director
|
+ 10000
|
2.021 USD |
|
5 years ago
Feb 22, 2019
|
Bought
150 K USD
|
LEVIN JEREMY M
CEO
|
+ 75000
|
2 USD |
|
6 years ago
Aug 14, 2018
|
Bought
62.3 K USD
|
Bernstein Karen
Director
|
+ 10000
|
6.23 USD |
|
6 years ago
Aug 14, 2018
|
Bought
32.4 K USD
|
WILLIAMS DOUGLAS E
Director
|
+ 5000
|
6.4883 USD |
|
7 years ago
Aug 25, 2017
|
Bought
110 K USD
|
LEVIN JEREMY M
CEO
|
+ 15334
|
7.15 USD |
7. News
Ovid Therapeutics (OVID) Reports Q3 Loss, Tops Revenue Estimates
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.20 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.16 per share a year ago.
zacks.com
- 2 months ago
Meg Alexander Takes on Expanded Role as President and COO at Ovid Therapeutics, Strengthening Leadership for Future Growth
NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today announced the promotion of Meg Alexander to President and Chief Operating Officer (COO). Alexander will work in collaboration with Ovid's leadership team to advance Ovid's development pipeline of potential disease-halting neurotherapeutics and define and execute its go-forward strategy.
globenewswire.com
- 4 months ago
Ovid Therapeutics (OVID) Upgraded to Buy: Here's Why
Ovid Therapeutics (OVID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
zacks.com
- 5 months ago
Shareholders In Ovid Therapeutics Inc Invited To Participate In Fraud Investigation With The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ:OVID) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
accesswire.com
- 5 months ago
Ovid Therapeutics Inc Investors Encouraged To Join Fraud Investigation With Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 18, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ:OVID) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
accesswire.com
- 5 months ago
Ovid Therapeutics Inc Shareholders Eligible To Participate In Fraud Investigation With Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 17, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ:OVID) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
accesswire.com
- 5 months ago
Ovid Therapeutics Inc Investors Invited To Join In Fraud Investigation With Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 16, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ:OVID) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
accesswire.com
- 5 months ago
Ovid Therapeutics Inc Shareholders Encouraged To Join Fraud Investigation With Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ: OVID ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
accesswire.com
- 5 months ago
Ovid Therapeutics Inc Shareholders Invited To Join Fraud Investigation With Schall Law Firm
The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ: OVID ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
accesswire.com
- 5 months ago
Ovid Therapeutics Inc Investors Welcome To Participate In Fraud Investigation With Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 14, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ovid Therapeutics Inc. ("Ovid" or "the Company") (NASDAQ: OVID ) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
accesswire.com
- 5 months ago
Ovid Therapeutics (OVID) Q2 Earnings and Revenues Surpass Estimates
Ovid Therapeutics (OVID) came out with quarterly earnings of $0.12 per share, beating the Zacks Consensus Estimate of a loss of $0.22 per share. This compares to loss of $0.18 per share a year ago.
zacks.com
- 5 months ago
Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results
NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, today reported business updates and financial results for the second quarter ended June 30, 2024.
globenewswire.com
- 5 months ago
8. Profile
Summary
Ovid Therapeutics Inc. OVID
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 52.5 M
Dividend Yield
0.00%
Description
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
Contact
1460 Broadway, New York, NY, 10036
https://www.ovidrx.com
IPO
Date
May 5, 2017
Employees
25
Officers
Mr. Tom Parry
Vice President of Research and Early Development
Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D.
Chief Executive Officer & Chairman
Dr. Julia Tsai Ph.D.
Senior Vice President of Clinical Development
Dr. Toshiya Nishi D.V.M.
Head of Epilepsy Research
Ms. Meg Alexander
President & Chief Operating Officer
Mr. Zhong Zhong Ph.D.
Chief Scientific Officer
Mr. Jeffrey A. Rona
Chief Business and Financial Officer
Dr. Dirk Haasner
Senior Vice President of Global Manufacturing & CMC QA
Garret Bonney
Investor Relations Officer